Endocrine Abstracts

Background: Since the FDA-approval of Lu177-DOTATATE and I131-MIBG radiopharmaceutical therapies in 2018, there is emerging real-world experience with their use. Only a few institutions in the US have both therapies available. Here, we describe our experience with these agents for patients with pheochromocytoma and paraganglioma (PPGL).Methods: This is a retrospective evaluation of all patients with progressive, metastatic, PPGL referred for radiopharmac...